From clinic tool to OTC glucose monitor for everyday feedback
Over-the-counter continuous glucose monitoring describes a new class of sensor-and-app systems that track glucose in real time without a prescription, extending from traditional diabetes management into general wellness and lifestyle feedback for people who do not use insulin. Dexcom Stelo sits at the center of this shift. The FDA first cleared Stelo in March 2024 as the first OTC continuous glucose monitor for adults who do not use insulin, then expanded clearance in June to people as young as two years old. These sensors sit under the skin and send glucose readings to a paired app about every 15 minutes, turning glucose data into another stream in wearable health tracking. Unlike noninvasive smartwatch features still under scrutiny, Stelo is an FDA‑cleared medical device, but it is marketed as a feedback tool rather than a replacement for clinical diabetes care.
Wellness promise vs. medical reality: who benefits most
The clearest upside of OTC glucose monitors remains in diabetes and prediabetes, where continuous glucose monitoring can reveal patterns that fingerstick tests miss. Stelo is not for people who use insulin or have problematic hypoglycemia, but it can support some people with diabetes on oral medication and people with prediabetes who want to see how meals, exercise, and sleep move their glucose. A 2026 systematic review found CGM use lowered mean glucose in non-diabetic users, with the benefit concentrated among people with prediabetes, and showed no significant effect on BMI. For healthy users without glucose issues, the data may be interesting but the clinical payoff is uncertain. These devices are FDA‑cleared as feedback tools, not as stand‑alone diabetes management apps, so users are told not to change medication or make treatment decisions without health‑care guidance.
Pediatrics, caregivers, and new rules for schools
Extending Dexcom Stelo to children turns an OTC glucose monitor into a policy question for parents, schools, and health teams. The sensor relies on a compatible smartphone or smart device, so it is not a standalone meter that works independent of apps, operating system updates, and connectivity. For children, the system should be used under adult caregiver supervision, and a caregiver’s phone can receive glucose values and trends every 15 minutes. Stelo does not provide low‑glucose alerts, which limits its role for high‑risk pediatric users but still makes it appealing for families tracking daily patterns. School IT and health administrators now have to decide whether caregiver-connected phones can remain nearby, how Wi‑Fi and phone bans during class or exams affect readings, and who responds when glucose data shows a concern in the middle of the school day.
The app ecosystem: privacy, data flows, and device limits
Every OTC continuous glucose monitoring system is also an app ecosystem, with cloud accounts, data‑sharing options, and sometimes coaching features layered over the sensor. HIPAA may protect data once it reaches a provider record, but not every consumer health or wellness app falls under those rules. Some CGM apps and related services instead fall under the FTC’s Health Breach Notification Rule, which still leaves users responsible for reading what the app collects, which partners receive it, and whether it feeds research, analytics, or advertising. FDA cyber guidance adds expectations for security planning and vulnerability management in connected medical devices, but the user-facing experience remains uneven. Stelo’s app, for example, depends on compatible iOS or Android versions and may connect to a smartwatch only when the phone is nearby, making software support and security updates as important as the sensor itself.
Toward a wearable health tracking stack that handles medical data
As OTC glucose monitors such as Dexcom Stelo and Abbott’s Lingo move into wellness marketing, they blur the line between medical device and lifestyle gadget. Wearable health tracking platforms now have to present medical‑grade glucose data alongside steps, sleep, and heart rate in ways that are clear but not alarmist. That means emphasizing trend views, context about meals and activity, and plain guidance that these systems are feedback tools, not diagnostic devices. For employers and health plans, questions about eligibility screening, reimbursement, and integration with diabetes management apps are only starting to surface. For schools and families, policies about phone access, caregiver oversight, and responsibility for responding to readings are becoming part of everyday life. The next phase for the ecosystem will be less about adding sensors and more about turning streams of glucose data into understandable, privacy‑aware insights for the people who stand to gain the most.
